Emtrix® is used to treat nail discoloration and damage caused by fungal nail infection or psoriasis. The product was launched in the Nordic countries during autumn 2010 under the Nalox™
brand.International launch under way through partners in more than 50 countries
Emtrix® is a solution applied to the damaged nail. Emtrix® is patented, and is based on proven compounds. Its effect and safety have been documented in several clinical trials. A placebo-controlled clinical trial involving 493 patients was completed in 2008, with positive results:
- 50% of the patients improved after two weeks' treatment
- 75% of the patients improved after six months' treatment
Nail fungus (onychomycosis), which can affect both toe- and fingernails, chiefly manifests itself in thickening and discoloration of the nails. Nail fungus is hard to treat, and the treatment time is often long, as it takes up to a year for a healthy new nail to grow out. The disease is common, affecting about 100 million patients in Europe and North America. Prevalence is about 10% in the general population and over 25% in the over-50s. About 40% of all patients with psoriasis are also affected by changes in the nail. Based on IMS data the total market is estimated to in excess of $1.4bn, despite the great majority of those infected being untreated.
The product is marketed in the U.S. by Moberg Pharma’s subsidiary Moberg Pharma North America LLC, and by distribution partners in Europe, the Middle East, Israel, Australia and several other countries, see our partners. For information on where to buy Nalox™, see www.nalox.se.
Emtestam, L., Kaaman, T. and Rensfeldt, K. (2012), Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. Mycoses. doi: 10.1111/j.1439-0507.2012.02215.x
Journal of Cosmetics, Dermatological Sciences and Applications, Vol. 1 No. 3, 2011